The initiative will focus on applying artificial intelligence, robotics, and data science to improve every stage of the pharmaceutical pipeline—from early-stage drug discovery to commercial manufacturing. Key goals include:
- Leveraging AI and machine learning to explore disease mechanisms and support personalized treatment design
- Accelerating the transition from Phase I clinical trials to manufacturing readiness
- Enhancing manufacturing with robotics and AI tools to ensure efficiency, compliance, and sustainability
- Strengthening workforce development through inclusive education and industry-focused training
Eli Lilly and Company and Purdue University have announced an expanded strategic partnership with a planned investment of up to $250 million over the next eight years. The new initiative, called the Lilly–Purdue 360 Initiative, is aimed at accelerating drug discovery, development, and manufacturing using AI and other advanced technologies. The collaboration could become the largest of its kind between an industry leader and an academic institution in the United States.
what makes this one of the most ambitious industry-academic alliances in the us
The existing agreement between Lilly and Purdue, originally set to expire in 2027, has been extended through 2032. Four new collaborative projects have been added, and Purdue will provide dedicated on-campus space for Lilly researchers in West Lafayette. In return, Purdue scientists will work inside Lilly facilities in Indianapolis and Indiana’s LEAP Research and Innovation District.
why talent development is central to lilly’s ai investment strategy
The Lilly Scholars at Purdue program, part of the expanded partnership, plays a critical role by supporting high-achieving students from underrepresented backgrounds who are preparing for careers in pharmaceutical manufacturing and research. This investment is expected to build a stronger, more diverse talent pipeline to serve Lilly and other Indiana employers.
how AI, Robotics and collaboration will shape next-gen drug development
The initiative aims to bridge laboratory science with clinical translation through AI-powered insights and technology-enabled scaling. This includes:
- Developing AI tools to predict molecule behavior and streamline discovery
- Using robotics and smart systems to reduce manual processes in manufacturing
- Reducing clinical trial failures and accelerating time to market with data-driven approaches
what leaders at purdue university and eli lilly are saying
“As potentially the largest single university-industry research agreement in American history, Lilly and Purdue are blazing a new trail to the endless frontier,” said Purdue University President Mung Chiang. “Today marks a monumental watershed in generating jobs, workforce, and innovation across America’s Hard Tech Corridor.”
David A. Ricks, chair and CEO of Lilly, added: “Accelerating the delivery of life-changing medicines demands a highly skilled workforce and continuous innovation across discovery, process development and manufacturing. Through this expanded collaboration with Purdue, we look forward to combining our strengths in advanced technologies and cutting-edge science to pioneer new methods of delivering next-generation medicines.”
about purdue university
Purdue University is a top-ranked public research university in the United States, known for its leadership in science, technology, and engineering. The university supports more than 107,000 students across multiple campuses and is recognized for initiatives such as One Health, Purdue Computes, and the Mitch Daniels School of Business.
about eli lilly and company
Eli Lilly and Company is a global pharmaceutical leader dedicated to advancing innovative medicines for diseases such as diabetes, cancer, and Alzheimer’s. With nearly 150 years of scientific expertise, Lilly is committed to improving human health through biotechnology, genetic medicine, and AI-enhanced drug development.
By
